Latest news with #Sezgin
Hans India
22-05-2025
- Health
- Hans India
Birth control pill may triple risk of cryptogenic stroke in women: Study
New Delhi: Taking birth control pills or combined oral contraceptives containing both oestrogen and progestin may triple the risk of cryptogenic stroke in young women, according to a study. Strokes without a known cause are called cryptogenic. It accounts for up to 40 per cent of all ischaemic strokes in young adults. Despite its prevalence, the contribution of sex-specific risk factors, such as contraceptive use, has remained underexplored. The findings add to a growing body of evidence linking hormonal contraception to vascular risk in women of reproductive age. 'Our findings confirm earlier evidence linking oral contraceptives to stroke risk,' said lead author Dr. Mine Sezgin, Department of Neurology, Istanbul University. 'What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved – possibly genetic or biological,' she added. The research included 268 women aged 18-49 years with cryptogenic ischaemic stroke (CIS) and 268 age-matched stroke-free controls across 14 centres in Europe. Of the participants, 66 patients and 38 controls were using combined combined oral contraceptives. While the researchers note that further prospective studies are needed, they advise clinicians to exercise caution when prescribing combined oral contraceptives to women with known vascular risk factors or a history of ischaemic stroke. 'Our findings should prompt more careful evaluation of stroke risk in young women, particularly those with additional risk factors,' Dr. Sezgin said. Next, the researchers plan to explore biological and genetic mechanisms underlying the observed association between combined oral contraceptive use and increased stroke risk to better understand how hormonal contraceptives may independently elevate stroke risk. The findings were presented at the ongoing European Stroke Organisation Conference (ESOC) 2025 in Helsinki, Finland.
Yahoo
21-05-2025
- Health
- Yahoo
ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows
HELSINKI, May 20, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that the use of combined oral contraceptives (OCs) is associated with a threefold increase in the risk of cryptogenic ischaemic stroke (CIS) in young women.(1) The findings add to a growing body of evidence linking hormonal contraception to vascular risk in women of reproductive age. Cryptogenic ischaemic stroke, which is stroke with no identifiable cause, accounts for up to 40% of all ischaemic strokes in young adults.(2) Despite its prevalence, the contribution of sex-specific risk factors, such as contraceptive use, has remained underexplored. While prior studies have associated combined OCs with stroke risk, this is among the few studies to focus specifically on cryptogenic stroke in young women. The Searching for Explanations for Cryptogenic Stroke in the Young (SECRETO) study included 268 women aged 18–49 years with CIS and 268 age-matched stroke-free controls across 14 centres in Europe. Of the participants, 66 patients and 38 controls were using combined OCs. After adjusting for age and established comorbidities such as hypertension, smoking, migraine with aura, and abdominal obesity, OC use was associated with an adjusted odds ratio of 3.00 (95% CI: 1.61–5.57). No significant interactions were found between OC use and these risk factors, suggesting that the increased stroke risk may operate independently of other known contributors. "Our findings confirm earlier evidence linking oral contraceptives to stroke risk," said Dr. Mine Sezgin, Department of Neurology, Istanbul University, and lead author of the study. "What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved – possibly genetic or biological." Most OC users in the study were taking ethinylestradiol-based formulations, with a median dose of 20 micrograms. Other types of estrogen, such as estradiol hemihydrate and estradiol valerate, were also recorded. "We calculated the equivalent estrogen dose for each patient to ensure consistency," Dr Sezgin explained. "While our data provides important initial insights, larger studies are needed to determine if certain formulations carry different levels of risk. This knowledge could help guide more personalised contraceptive choices for women." While the researchers note that further prospective studies are needed, they advise clinicians to exercise caution when prescribing combined OCs to women with known vascular risk factors or a history of ischaemic stroke. "Our findings should prompt more careful evaluation of stroke risk in young women, particularly those with additional risk factors," concluded Dr. Sezgin. Moving forward, the researchers plan to explore biological and genetic mechanisms underlying the observed association between combined OC use and increased stroke risk to better understand how hormonal contraceptives may independently elevate stroke risk. Note to editors: A reference to ESOC 2025 must be included in all coverage and/or articles associated with this study. About the study author: Dr. Mine Sezgin is a neurologist and stroke researcher based at the Istanbul University Faculty of Medicine. Her work focuses on sex-specific risk factors and stroke prevention in young adults. About the European Stroke Organisation (ESO): The ESO is a pan-European society of stroke researchers and physicians, national and regional stroke societies and lay organisations that was founded in December 2007. The aim of the ESO is to reduce the burden of stroke by changing the way that stroke is viewed and treated. This can only be achieved by professional and public education, and by making institutional changes. ESO serves as the voice of stroke in Europe, harmonising stroke management across the whole of Europe and taking action to reduce the burden of stroke regionally and globally. References: 1. Sezgin, M., et al. Hormonal contraception increases the risk of cryptogenic stroke in young women. Abstract O049, presented at the European Stroke Organisation Conference; 21 May 2025; Vienna, Austria. 2. Yaghi, S., & Elkind, M. S. (2014). Cryptogenic stroke: A diagnostic challenge. Neurology. Clinical practice, 4(5), 386–393. View original content: SOURCE European Stroke Organisation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Korea Herald
21-05-2025
- Health
- Korea Herald
ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows
, May 21, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that the use of combined oral contraceptives (OCs) is associated with a threefold increase in the risk of cryptogenic ischaemic stroke (CIS) in young women. (1) The findings add to a growing body of evidence linking hormonal contraception to vascular risk in women of reproductive age. Cryptogenic ischaemic stroke, which is stroke with no identifiable cause, accounts for up to 40% of all ischaemic strokes in young adults. (2) Despite its prevalence, the contribution of sex-specific risk factors, such as contraceptive use, has remained underexplored. While prior studies have associated combined OCs with stroke risk, this is among the few studies to focus specifically on cryptogenic stroke in young women. The Searching for Explanations for Cryptogenic Stroke in the Young (SECRETO) study included 268 women aged 18–49 years with CIS and 268 age-matched stroke-free controls across 14 centres in Europe. Of the participants, 66 patients and 38 controls were using combined OCs. After adjusting for age and established comorbidities such as hypertension, smoking, migraine with aura, and abdominal obesity, OC use was associated with an adjusted odds ratio of 3.00 (95% CI: 1.61–5.57). No significant interactions were found between OC use and these risk factors, suggesting that the increased stroke risk may operate independently of other known contributors. "Our findings confirm earlier evidence linking oral contraceptives to stroke risk," said Dr. Mine Sezgin, Department of Neurology, Istanbul University, and lead author of the study. "What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved – possibly genetic or biological." Most OC users in the study were taking ethinylestradiol-based formulations, with a median dose of 20 micrograms. Other types of estrogen, such as estradiol hemihydrate and estradiol valerate, were also recorded. "We calculated the equivalent estrogen dose for each patient to ensure consistency," Dr Sezgin explained. "While our data provides important initial insights, larger studies are needed to determine if certain formulations carry different levels of risk. This knowledge could help guide more personalised contraceptive choices for women." While the researchers note that further prospective studies are needed, they advise clinicians to exercise caution when prescribing combined OCs to women with known vascular risk factors or a history of ischaemic stroke. "Our findings should prompt more careful evaluation of stroke risk in young women, particularly those with additional risk factors," concluded Dr. Sezgin. Moving forward, the researchers plan to explore biological and genetic mechanisms underlying the observed association between combined OC use and increased stroke risk to better understand how hormonal contraceptives may independently elevate stroke risk. Note to editors: A reference to ESOC 2025 must be included in all coverage and/or articles associated with this study. About the study author: Dr. Mine Sezgin is a neurologist and stroke researcher based at the Istanbul University Faculty of Medicine. Her work focuses on sex-specific risk factors and stroke prevention in young adults. About the European Stroke Organisation (ESO): The ESO is a pan-European society of stroke researchers and physicians, national and regional stroke societies and lay organisations that was founded in December 2007. The aim of the ESO is to reduce the burden of stroke by changing the way that stroke is viewed and treated. This can only be achieved by professional and public education, and by making institutional changes. ESO serves as the voice of stroke in Europe, harmonising stroke management across the whole of Europe and taking action to reduce the burden of stroke regionally and globally. 1. Sezgin, M., et al. Hormonal contraception increases the risk of cryptogenic stroke in young women. Abstract O049, presented at the European Stroke Organisation Conference; 21 May 2025; Vienna, Austria. 2. Yaghi, S., & Elkind, M. S. (2014). Cryptogenic stroke: A diagnostic challenge. Neurology. Clinical practice, 4 (5), 386–393.
Scottish Sun
20-05-2025
- Health
- Scottish Sun
Common medication taken by millions of Brits linked to triple risk of deadly stroke
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) THE combined pill has been linked to triple the risk of sudden stroke in young women, a new study has revealed. It's already well established that the pill, taken by over 3 million women in the UK, can increase the risk of blood clots and heart issues. 1 The combined pill could triple the risk of sudden stroke in young women Credit: Getty Now, scientists based in Turkey have also linked it to a higher chance of cryptogenic ischaemic stroke (CIS) - a type of brain bleed with no clear cause. The new findings were presented at the European Stroke Organisation Conference in Helsinki, Finland today (May 20). Researchers from Istanbul University looked at 268 women aged 18 to 49 who had sudden, unexplained strokes, and compared them to 268 women of the same age who hadn't had a stroke. Among those who had strokes, 66 were using the combined contraceptive pill compared to just 38 in the control group. After accounting for factors like smoking, high blood pressure, migraines and obesity, they found women on the pill were three times more likely to suffer a cryptogenic stroke. The combined pill contains oestrogen and progestogen - and it's the oestrogen that's been linked to a higher risk of blood clots, which can lead to strokes. However, strokes in younger people are rare, and the overall risk from using the pill is very low, according to the Stroke Association. It's important to always speak to your doctor and pharmacist when thinking of coming off a medication. Earlier this year, a Danish study suggested the combined pill increases the risk of stroke two-fold. But in this study, experts have found a link to cryptogenic strokes, specifically. The 2 forms of contraceptive 'most likely to trigger deadly heart attack and stroke' revealed 'Our findings confirm earlier evidence linking oral contraceptives to stroke risk,' said Dr Mine Sezgin, lead author of the study. 'What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved – possibly genetic or biological.' The experts said more studies are needed to firmly establish the link. But they also urged doctors to be careful when prescribing combined oral contraceptives to women with existing stroke risks or a history of ischaemic stroke. 'Our findings should prompt more careful evaluation of stroke risk in young women, particularly those with additional risk factors,' Dr Sezgin, said.
Yahoo
20-05-2025
- Health
- Yahoo
ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows
HELSINKI, May 20, 2025 /CNW/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that the use of combined oral contraceptives (OCs) is associated with a threefold increase in the risk of cryptogenic ischaemic stroke (CIS) in young women.(1) The findings add to a growing body of evidence linking hormonal contraception to vascular risk in women of reproductive age. Cryptogenic ischaemic stroke, which is stroke with no identifiable cause, accounts for up to 40% of all ischaemic strokes in young adults.(2) Despite its prevalence, the contribution of sex-specific risk factors, such as contraceptive use, has remained underexplored. While prior studies have associated combined OCs with stroke risk, this is among the few studies to focus specifically on cryptogenic stroke in young women. The Searching for Explanations for Cryptogenic Stroke in the Young (SECRETO) study included 268 women aged 18–49 years with CIS and 268 age-matched stroke-free controls across 14 centres in Europe. Of the participants, 66 patients and 38 controls were using combined OCs. After adjusting for age and established comorbidities such as hypertension, smoking, migraine with aura, and abdominal obesity, OC use was associated with an adjusted odds ratio of 3.00 (95% CI: 1.61–5.57). No significant interactions were found between OC use and these risk factors, suggesting that the increased stroke risk may operate independently of other known contributors. "Our findings confirm earlier evidence linking oral contraceptives to stroke risk," said Dr. Mine Sezgin, Department of Neurology, Istanbul University, and lead author of the study. "What's particularly notable is that the association remains strong even when accounting for other known risk factors, which suggests there may be additional mechanisms involved – possibly genetic or biological." Most OC users in the study were taking ethinylestradiol-based formulations, with a median dose of 20 micrograms. Other types of estrogen, such as estradiol hemihydrate and estradiol valerate, were also recorded. "We calculated the equivalent estrogen dose for each patient to ensure consistency," Dr Sezgin explained. "While our data provides important initial insights, larger studies are needed to determine if certain formulations carry different levels of risk. This knowledge could help guide more personalised contraceptive choices for women." While the researchers note that further prospective studies are needed, they advise clinicians to exercise caution when prescribing combined OCs to women with known vascular risk factors or a history of ischaemic stroke. "Our findings should prompt more careful evaluation of stroke risk in young women, particularly those with additional risk factors," concluded Dr. Sezgin. Moving forward, the researchers plan to explore biological and genetic mechanisms underlying the observed association between combined OC use and increased stroke risk to better understand how hormonal contraceptives may independently elevate stroke risk. Note to editors: A reference to ESOC 2025 must be included in all coverage and/or articles associated with this study. About the study author: Dr. Mine Sezgin is a neurologist and stroke researcher based at the Istanbul University Faculty of Medicine. Her work focuses on sex-specific risk factors and stroke prevention in young adults. About the European Stroke Organisation (ESO): The ESO is a pan-European society of stroke researchers and physicians, national and regional stroke societies and lay organisations that was founded in December 2007. The aim of the ESO is to reduce the burden of stroke by changing the way that stroke is viewed and treated. This can only be achieved by professional and public education, and by making institutional changes. ESO serves as the voice of stroke in Europe, harmonising stroke management across the whole of Europe and taking action to reduce the burden of stroke regionally and globally. References: 1. Sezgin, M., et al. Hormonal contraception increases the risk of cryptogenic stroke in young women. Abstract O049, presented at the European Stroke Organisation Conference; 21 May 2025; Vienna, Austria. 2. Yaghi, S., & Elkind, M. S. (2014). Cryptogenic stroke: A diagnostic challenge. Neurology. Clinical practice, 4(5), 386–393. View original content: SOURCE European Stroke Organisation View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
